Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge
Open Access
- 1 October 2020
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 99, 28-33
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (K24-AI145661, 5T32AI052074-13)
This publication has 20 references indexed in Scilit:
- Covid-19 in Critically Ill Patients in the Seattle Region — Case SeriesNew England Journal of Medicine, 2020
- COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposalThe Journal of Heart and Lung Transplantation, 2020
- Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020MMWR. Morbidity and Mortality Weekly Report, 2020
- Clinical and immunological features of severe and moderate coronavirus disease 2019Journal of Clinical Investigation, 2020
- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, ChinaIntensive Care Medicine, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathologySeminars in Immunopathology, 2017
- Profile of sarilumab and its potential in the treatment of rheumatoid arthritisDrug Design, Development and Therapy, 2017
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Plasmacytoid Dendritic Cells Induce Plasma Cell Differentiation through Type I Interferon and Interleukin 6Immunity, 2003